WHAT IS CLAIMED IS:

1. A compound of Formula (I) or Formula (II)



(I)

or



(II)

or a pharmaceutically acceptable salt thereof, wherein

A and B are each independently selected from the group consisting of CH_2, N and O;

D and E are each independently selected from the group consisting of N and O;

F is selected from the group consisting of phenyl and heteroaryl (pyridyl)

G a bond or is methylene, wherein the methylene optionally substituted with a substituent selected from methyl, ethyl, isopropyl, and carbonyl;

R is selected from the group consisting of

(a) H,

(b) CF_3,

(c) CH_3;

R^1 is selected from the group consisting of

(a) hydrogen,

(b) CF_3,

(c)phenyl,

(d) $-C_{1-6}$alkyl,

(e) $-C_{3-6}$cycloalkyl,

(f) $-C_{2-6}$alkenyl,

(g) $-C_{2-6}$alkynyl,

(h) $-O-C_{1-6}$alkyl,

(i) $-O-C_{2-6}$alkenyl,

(j) $-S-C_{1-6}$alkyl, and

(k) a heteroaromatic ring of 5 or 6 members, wherein the heteroaromatic ring comprises 1, 2 or 3 heteroatoms independently selected from the group consisting of N, and O, wherein the heteroaryl is optionally substituted with methyl, methoxy, hydroxyl or halo;

R^2 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-6}$alkyl,

(c) heteroaromatic ring of 5 or 6 members, wherein the heterocycloalkyl or heteroaromatic ring comprises 1, 2 or 3 heteroatoms independently selected from the group consisting of N, and O,

(d) aryl, and

(e) $-NR^5R^6$;

R^3 is selected from the group consisting of

(a) hydrogen,

(b) $-C_{1-6}$alkyl,

(c) heteroaromatic ring of 5 or 6 members, wherein the heterocycloalkyl or heteroaromatic ring comprises 1, 2 or 3 heteroatoms independently selected from the group consisting of N, and O,

(d) aryl, and

(e) $-NR^5R^6$,

wherein R^2 and R^3 choices (a), (b), (c), (d) and (e) are each optionally substituted with one or two substituents selected from methyl, methoxy, halo and hydroxyl,

or R^2 and R^3 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl and cyclohexyl;

R^4 is –NH(C_{1-3}alkylaryl), optionally substituted with one or two substituents selected from the group consisting of halo, hydroxyl, –C_{1-6}alkyl and –O–C_{1-6}alkyl;

R^7 is selected from the group consisting of

(a) hydroxyl,

(b) $N(CH_3)_2$,

(c) Aryl,

(d) a heteroaromatic ring of 5 or 6 members, wherein the heteroaromatic ring comprises 1, 2 or 3 heteroatoms independently selected from the group consisting of N and O,

wherein R^7 choice (b), (c) and (d) is optionally substituted with methyl, methoxy, hydroxyl or halo.

2. A compound according to claim 1 of Formula (I)



(I)

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 2 wherein:

D and E are N.

4. A compound according to claim 2 wherein:

G is methylene, wherein the methylene optionally substituted with a substituent selected from methyl, ethyl, isopropyl, and carbonyl.

5. A compound according to claim 2 wherein:

R^1 is selected from the group consisting of

(a) hydrogen,

(b) CF_3,

(c) phenyl,

(d) $-C_{1-3}$alkyl,

(e) $-C_{3-6}$cycloalkyl.

6. A compound according to claim 2 wherein:

R^2 and R^3 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl and cyclohexyl.

7. A compound according to claim 2 wherein:

R^4 is $-NH(C_{1-3}$alkylphenyl), optionally substituted with one or two substituents selected from the group consisting of halo, hydroxyl, $-C_{1-6}$alkyl and $-O-C_{1-6}$alkyl.

8. A compound according to claim 2 wherein at least one of R^2 and R^3 is phenyl.

9. A compound according to claim 2 wherein:

A and B are each independently selected from the group consisting of CH_2 and N;

D and E are each independently selected from the group consisting of N;

F is selected from the group consisting of phenyl and pyridyl;

G a bond or is methylene, wherein the methylene optionally substituted with a substituent selected from methyl, ethyl, isopropyl, and carbonyl;

R is selected from the group consisting of

(a) H,

(b) CF_3,

(c) CH_3;

R^1 is selected from the group consisting of

(a) hydrogen,

(b) CF_3,

(c) phenyl,

(d) $-C_{1-3}$alkyl;

R^2 and R^3 are joined so that together with the atoms to which they are attached there is formed a ring selected from phenyl and cyclohexyl;

R^4 is –NH(C_{1-3}alkylphenyl), optionally substituted with one or two substituents selected from the group consisting of halo, hydroxyl, –C_{1-6}alkyl and –O–C_{1-6}alkyl.

10. A compound according to claim 1 wherein:

Within this aspect there is also a genus of compounds of Formula (II):



(II)

or a pharmaceutically acceptable salts thereof.

11. A compound according to claim 10 wherein:

D and E are N.

12. A compound according to claim 10 wherein:

G is methylene, wherein the methylene optionally substituted with a substituent selected from methyl, ethyl, isopropyl, and carbonyl.

13. A compound according to claim 10 wherein:

R^4 is –NH(C_{1-3}alkylphenyl), optionally substituted with one or two substituents selected from the group consisting of halo, hydroxyl, –C_{1-6}alkyl and –O–C_{1-6}alkyl.

14. A compound according to claim 10 wherein:

R^7 is pyrrole, pyridine, or imidazole.aoptionally substituted with one or two substituents selected from methyl, methoxy, hydroxyl and halo.

15. A compound according to claim 10 wherein:

D and E are N;

G is methylene, wherein the methylene optionally substituted with a substituent selected from methyl, ethyl, isopropyl, and carbonyl;

R^4 is —NH(C_{1-3}alkylphenyl), optionally substituted with one or two substituents selected from the group consisting of halo, hydroxyl, –C_{1-6}alkyl and –O–C_{1-6}alkyl;

R^7 is pyrrole, pyridine, or imidazole.aoptionally substituted with one or two substituents selected from methyl, methoxy, hydroxyl and halo.

16. A compound according to claim 1 selected from the group consisting of:













or a pharmaceutically acceptable salt thereof.

17. A pharmaceutical composition for treating an indication mediated by the binding of an $\alpha_2\delta$ subunit of voltage gated calcium channel, comprising a therapeutically effective amount a of a compound according to claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable acrrier.

18. A composition according to claim 16, said composition further comprising i) an opiate agonist, ii) an opiate antagonist, iii) an mGluR5 antagonist, iv) a 5HT receptor agonist, v) a 5HT receptor antagonist, vi) a sodium channel antagonist, vii) an NMDA receptor agonist, viii) an NMDA receptor antagonist, ix) a COX-2 selective inhibitor, x) an NK1 antagonist, xi) a non-steroidal anti-inflammatory drug, xii) a GABA-A receptor modulator, xiii) a dopamine agonist, xiv) a dopamine antagonist, xv) a selective serotonin reuptake inhibitor, xvi) a tricyclic antidepressant drug, xvii) a norepinephrine modulator, xviii) L-DOPA, xix) buspirone, xx) a lithium salt, xxi) valproate, xxii)

neurontin, xxiii) olanzapine, xxiv) a nicotinic agonist, xxv) a nicotinic antagonist, xxvi) a muscarinic agonist, xxvii) a muscarinic antagonist, xxviii) a selective serotonin and norepinephrine reuptake inhibitor (SSNRI), xxix) a heroin substituting drug, xxx) disulfiram, or xxxi) acamprosate.

19. A composition according to claim 17, wherein said heroin substituting drug is methadone, levo-alpha-acetylmethadol, buprenorphine or naltrexone.

20. A method of treatment of neuropathic pain comprising a step of administering an effective amount of a compound according to claim 1.

21. A method of treatment or prevention of pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

22. A method of treatment or prevention of a pain disorder wherein said pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain, or neuropathic pain, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

23. A method of treatment or prevention of anxiety, depression, bipolar disorder, psychosis, drug withdrawal, tobacco withdrawal, memory loss, cognitive impairment, dementia, Alzheimer's disease, schizophrenia or panic comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

24. A method of treatment or prevention of disorders of extrapyramidal motor function comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

25. The method of claim 24 wherein said disorder of extrapyramidal motor function is Parkinson's disease, progressive supramuscular palsy, Huntington's disease, Gilles de la Tourette syndrome, or tardive dyskinesia.

26. A method of treatment or prevention of anxiety disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

27. A method of claim 26 wherein said anxiety disorder is panic attack, agoraphobia or specific phobias, obsessive-compulsive disorders, post-traumatic stress disorder, acute stress disorder, generalized anxiety disorder, eating disorder, substance-induced anxiety disorder, or nonspecified anxiety disorder.

28. A method of treatment or prevention of neuropathic pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

29. A method of treatment or prevention of Parkinson's Disease comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

30. A method of treatment or prevention of depression comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

31. A method of treatment or prevention of epilepsy comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

32. A method of treatment or prevention of inflammatory pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

33. A method of treatment or prevention of cognitive dysfunction comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

34. A method of treatment or prevention of drug addiction, drug abuse and drug withdrawal comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

35. A method of treatment or prevention of bipolar disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

36. A method of treatment or prevention of circadian rhythm and sleep disorders comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

37. The method of Claim 36 wherein the circadian rhythm and sleep disorders are shift-work induced sleep disorder or jet-lag.